Lyrica
Product Images NDC 68258-7980

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 68258-7980). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ndc 68258-7980-09 (Ndc 68258 7980 09 Pfizer)

Ndc 68258-7980-09 (Ndc 68258 7980 09 Pfizer)
The text describes medication information for bulk source data of LYRICA 75 mg capsules manufactured by Pfizer Pharmaceuticals LLC in Vega Baja, PR. Each capsule contains 75mg of PREGABALIN and may cause drowsiness. The medication should be taken orally every few hours, avoiding alcohol consumption. The capsules are dispensed with medication guide and stored in a tight/light-resistant container. They are sold in 90 capsules with NDC numbers 68258-7980-09 and 68268-7980-09. The medication may be habit-forming and is only for the patient for whom it was prescribed. The text also contains a caution regarding the transfer of the drug to anyone other than the patient. There is information regarding the RX and lot numbers, and expiration date. The medication should be kept out of children's reach and stored at 77°F. The text also includes the address for Pfizer Pharmaceuticals LLC in Santa Ana, CA 92704.*
FDA Label Image

Figure (Lyrica 01)

Figure (Lyrica 01)
FDA Label Image

Chemical Structure (Lyrica 02)

Chemical Structure (Lyrica 02)
FDA Label Image

Figure 1 (Lyrica 03)

Figure 1 (Lyrica 03)
This is a data table that shows the percentage of patients who have improved in their pain from baseline. However, due to the errors, it is difficult to understand the information presented in the table.*
FDA Label Image

Figure 2 (Lyrica 04)

Figure 2 (Lyrica 04)
FDA Label Image

Figure 3 (Lyrica 05)

Figure 3 (Lyrica 05)
FDA Label Image

Figure 4 (Lyrica 06)

Figure 4 (Lyrica 06)
FDA Label Image

Figure 5 (Lyrica 07)

Figure 5 (Lyrica 07)
This text is not readable due to errors.*
FDA Label Image

Figure 6 (Lyrica 08)

Figure 6 (Lyrica 08)
FDA Label Image

Figure 7 (Lyrica 09)

Figure 7 (Lyrica 09)
FDA Label Image

Figure 8 (Lyrica 10)

Figure 8 (Lyrica 10)
FDA Label Image

Figure 9 (Lyrica 11)

Figure 9 (Lyrica 11)
FDA Label Image

Figure 10 (Lyrica 12)

Figure 10 (Lyrica 12)
The text provided is displaying a graph or chart that shows the percentage of subjects improved over the course of 12 weeks. The numbers at the bottom appear to be the value ranges, and the "Percent Improved" text suggests that this is a graph showing improvement percentages. However, it is difficult to interpret the data accurately due to inconsistent spacing and unclear formatting. Therefore, it is not possible to provide a complete and accurate description.*
FDA Label Image

Figure 11 (Lyrica 13)

Figure 11 (Lyrica 13)
This is a statistical report presenting the percentage of subjects improved, with values ranging from 0 to 100. There are also two columns identified as "Pregabalin" and "Placebo", which may refer to different treatments or conditions. No further information or context is provided.*
FDA Label Image

Logo (Lyrica 14)

Logo (Lyrica 14)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.